Lung Cancer Mutation Panel, Liquid Biopsy, InVisionFirst®, Resolution ctDx Lung™
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is one of the leading causes of cancer-related mortality. Accurate molecular characterization is critical for guiding treatment decisions, particularly with the emergence of targeted therapies and immunotherapies that have shown superiority over traditional chemotherapy in many cases. However, conventional tissue biopsy methods are often invasive, require larger tissue samples, and may not always be feasible due to tumor location or patient condition.
InVisionFirst®-Lung is a liquid biopsy test designed to address these challenges by utilizing circulating tumor DNA (ctDNA) derived from NSCLC tumors. This test detects alterations in 37 clinically relevant genes, including ALK, BRAF, EGFR, ERBB2, RET, KRAS, MET, ROS1, and others. The assay employs tagged-amplicon next-generation sequencing (NGS) technology to identify single nucleotide variants (SNVs), small insertions and deletions (indels), structural variants (SVs), copy number variants (CNVs), and gene fusions.
Clinical validation studies, such as the ACCELERATE trial, have demonstrated that InVisionFirst significantly reduces the time to treatment initiation compared to tissue-based methods, supporting its role as a valuable tool in genotyping NSCLC for therapy selection. Common mutations tested are, SNVs + indel hotspots: ALK, AKT1, BRAF, CCND1, CTNNB1, EGFR, ERBB2, ESR1, FGFR2, FGFR3, GATA3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KRAS, KIT, MAP2K1, MET, MYC, NFE2L2, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PPP2R1A, ROS1, U2AF1 SNVs + indel exon coverage: PTEN (70%), CDKN2A, STK11, TP53 (88-100%) Fusions: ALK, NTRK1, RET, ROS1 CNV: EGFR, ERBB2, FGFR1, MET including exon 14 deletion
The Resolution ctDx Lung assay was developed to provide patients and clinicians with information that can drive care decisions. With targeted therapies available for many of the driver mutations in NSCLC, its critical to determine which mutation is driving the cancer. Some of these therapies are second generation and overcome known resistance mutations to earlier therapies, such as EGFR T790M or ALK L1196M or ALK G1269A. The liquid biopsy allows for serial, near real-time assessment of the tumor genotype as the tumor evolves under therapy. The Resolution ctDx Lung assay includes all actionable genes, genes with driver mutations targeted by a specific FDA-approved therapy or therapies now in clinical trials.
- Provides comprehensive molecular profiling for NSCLC patients
- Aids in the selection of targeted therapies and immunotherapies
Test results provide a personalized molecular profile, including:
- A list of detected genetic variations.
- Recommended targeted therapies and immunotherapies based on identified mutations.
- Information on clinical trials available for the patient's genetic profile.
A negative result does not exclude the presence of actionable mutations, as ctDNA may not always be detectable in all cases due to tumor shedding variability.
Not applicable (results depend on individual tumor profiles).
Whole blood (2 tubes, 10 mL each).
Stability
- Ambient: Not recommended
- Refrigerated: 3-5 days
- Frozen: Not recommended
- JAMA Netw Open. 2023 Jul 3;6(7). [PMID: 37490292]
- Clin Cancer Res. 2016 Feb 15;22(4):915-22. [PMID: 26459174]
- Curr Treat Options Oncol. 2019 Jun 15;20(7):61. [PMID: 31203467]
- JCO Precis Oncol. 2020 Apr 2;4:PO.19.00281. [PMID: 32923908]
- PLoS One. 2018 Mar 15;13(3):e0193802. [PMID: 29543828]
- JCO Precis Oncol. 2019 Apr 25;3:PO.18.00299. [PMID: 32914040]
- Br J Cancer. 2017 Mar 14;116(6):802-810. [PMID: 28170370]